相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).
Shun Lu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
M. Schuler et al.
ANNALS OF ONCOLOGY (2020)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Ravi Salgia et al.
CANCER TREATMENT REVIEWS (2020)
Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
Tobias Raphael Overbeck et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Targeting MET Dysregulation in Cancer
Gonzalo Recondo et al.
CANCER DISCOVERY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Qiming Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
Enriqueta Felip et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
Eng-Huat Tan et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
J. Goldman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
M. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Rafael Caparica et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Samuel J. Klempner et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
A. Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models
Suzane L. Um et al.
CANCER RESEARCH (2017)
Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy
Ki-Hyun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib
Evan Barry et al.
CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Joel W. Neal et al.
LANCET ONCOLOGY (2016)
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2016)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S. Heist et al.
ONCOLOGIST (2016)
Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET plus non-small cell lung cancer (NSCLC).
Martin H. Schuler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Russell W. Jenkins et al.
CLINICAL LUNG CANCER (2015)
Onartuzumab in lung cancer: the fall of Icarus?
Christian Rolfo et al.
Expert Review of Anticancer Therapy (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
MET-Mutated NSCLC with Major Response to Crizotinib
Melody A. Mendenhall et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
MET Mutation Associated with Responsiveness to Crizotinib
Saiama N. Waqar et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Yilong Zhang et al.
BIOMEDICINES (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299) an anti-HGF antibody in an intracranial glioblastoma model
Kristan A. Meetze et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The biological role of HGF-MET axis in tumor growth and development of metastasis
Ewa Lesko et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
DNA copy number amplification profiling of human neoplasms
S. Myllykangas et al.
ONCOGENE (2006)
MET overexpression turns human primary osteoblasts into osteosarcomas
Salvatore Pantane et al.
CANCER RESEARCH (2006)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice
R Wang et al.
JOURNAL OF CELL BIOLOGY (2001)
分享论文
